New vaccine targets group a strep in first human test
NCT ID NCT07616934
First seen Jun 01, 2026 · Last updated Jun 23, 2026 · Updated 3 times
Summary
This early-stage trial is testing a new vaccine called VAX-A1 in 80 healthy adults aged 18 to 40. The goal is to see if the vaccine is safe and triggers an immune response against Group A Streptococcus bacteria, which cause strep throat and more severe illnesses. Participants will receive either a low, mid, or high dose of the vaccine or a placebo, and be monitored for side effects and antibody levels over six months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GROUP A STREPTOCOCCAL INFECTION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fusion Clinical Research
RECRUITINGAdelaide, South Australia, 5067, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
VAX-A1 vaccine
What this could lead to
If successful, this could lead to a vaccine that prevents Group A Strep infections, which can cause sore throats, scarlet fever, and serious complications like rheumatic fever.
What could go wrong
This is a very early Phase 1 trial with only 80 healthy adults. It is primarily testing safety and immune response, not whether the vaccine actually prevents infection. Many vaccines fail in early testing.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.